Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4

November 12, 2021 at 13:30 PM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and it’s most ambitious yet
This study builds on the HYPER-H21-1 and HYPER-H21-2 findings, as well as the HYPER-H21-3 study that is set to begin dosing in mid-November 2021
Lexaria’s goal is to pursue regulatory approval for its proprietary DehydraTECH-CBD for potential use as a treatment for high blood pressure
Study protocols are being readied for submission to the IRB, and approval is expected by January 2022

Lexaria Bioscience (NASDAQ: LEXX) has, so far in 2021, embarked on several studies geared towards evaluating its proprietary DehydraTECH(TM) CBD for the potential treatment of hypertension and heart disease.

Results from the first hypertension study, HYPER-H21-1, were released on July 29, 2021, showing that the administration of a single dose of 300 mg of DehydraTECH-CBD resulted in a significant reduction in blood pressure from baseline. Of the 24 adult volunteers in…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CanadianCannabisWire is part of the InvestorBrandNetwork.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol

Price

Change (%)

AMZN

271.58

+36.08 (15.32%)

AAPL

308.91

-24.52 (-7.35%)

AMD

476.15

-9.24 (-1.90%)

BAC

61.95

+0.22 (0.36%)

GOOG

356.65

+22.97 (6.88%)